Upgrade to SI Premium - Free Trial

TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

September 24, 2026 12:20 PM
TD Cowen analyst Ritu Baral reiterated a Buy rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles